Communications Biology,
Год журнала:
2024,
Номер
7(1)
Опубликована: Апрель 1, 2024
Abstract
Multimodal
nanoparticles,
utilizing
quantum
dots
(QDs),
mesoporous
silica
nanoparticles
(MSNs),
and
gold
(Au
NPs),
offer
substantial
potential
as
a
smart
targeted
drug
delivery
system
for
simultaneous
cancer
therapy
imaging.
This
method
entails
coating
magnetic
GZCIS/ZnS
QDs
with
silica,
loading
epirubicin
into
the
pores,
capping
Au
NPs,
PEGylation,
conjugating
epithelial
cell
adhesion
molecule
(EpCAM)
aptamers
to
actively
target
colorectal
(CRC)
cells.
study
showcases
hybrid
QD@MSN-EPI-Au-PEG-Apt
nanocarriers
(size
~65
nm)
comprehensive
characterizations
post-synthesis.
In
vitro
studies
demonstrate
selective
cytotoxicity
of
these
towards
HT-29
cells
compared
CHO
cells,
leading
significant
reduction
in
survival
when
combined
irradiation.
Targeted
vivo
is
validated
by
enhanced
anti-tumor
effects
reduced
side
following
chemo-radiotherapy,
along
imaging
CRC
mouse
model.
approach
holds
promise
improved
theranostics.
Cancer Nanotechnology,
Год журнала:
2024,
Номер
15(1)
Опубликована: Апрель 5, 2024
Abstract
Background
Colorectal
cancer
(CRC)
ranks
as
the
third
most
common
globally
and
second
leading
cause
of
cancer-related
mortality.
Traditional
chemotherapy,
while
effective,
often
results
in
significant
side
effects,
highlighting
need
for
more
efficient
therapies.
Recent
advancements
nanotechnology
have
led
to
development
strategies
that
aim
minimize
toxicity
normal
cells
by
precise
targeting
cells.
In
this
context,
cobalt
oxide
nanoparticles
(Co
3
O
4
NPs)
shown
promising
anticancer
potential.
Our
study
focuses
on
evaluating
antioxidant,
antibacterial,
properties
Co
NPs
synthesized
using
Vibrio
sp.
VLC,
a
bioluminescent
bacterium.
Results
XRD
FTIR
analyses
confirmed
successful
synthesis
NPs,
which
displayed
spherical
morphology
with
an
average
diameter
60
nm.
The
demonstrated
antioxidant
antibacterial
activities.
MTT
assay
indicated
caused
dose-
time-dependent
against
CT26
cells,
exhibiting
relatively
lower
towards
vivo
experiments
further
tumor
suppressive
effects
BALB/c
mice,
minimal
liver,
spleen,
kidney
tissues
compared
widespread
cisplatin.
Conclusion
This
verifies
their
potent
biosynthesized
represent
targeted
method
CRC
therapy.
However,
research
is
needed
elucidate
mechanism
action
also
application
clinical
phase.
Graphical
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(3), С. 970 - 970
Опубликована: Янв. 24, 2025
This
study
investigates
the
biodistribution
of
polysaccharide-based
nanoparticles
loaded
with
epirubicin
(POLEPI)
compared
to
hydrochloride
(EPI)
in
naïve
female
nude
mice
following
a
single
intravenous
dose.
The
inherent
fluorescence
was
tracked
using
Newton
7
animal
imager
and
Varioskan.
Initial
whole-animal
optical
imaging
failed
reliably
detect
distribution,
necessitating
ex
vivo
key
tissues
harvested
at
intervals
between
10
min
48
h
post-injection.
Optimal
conditions
were
established
5
s
exposure
time
excitation
(Ex)/emission
(Em)
480
nm/550
nm.
POLEPI
further
evaluated
both
immunocompromised
bearing
patient-derived
ovarian
tumors.
Unlike
epirubicin,
exhibited
notable
tissue
distribution
within
3
By
h,
signals
undetectable
models,
although
non-tumored
animals
persistent
signals.
In
liver
primary
organ
for
accumulation,
lower
levels
tumored
mice.
Interestingly,
brain
higher
POLEPI-treated
those
receiving
epirubicin.
Neither
nor
accumulated
spleen
or
bone
marrow.
tumors,
peaked
24
2.1
times
than
epirubicin-treated
group
over
period.
Furthermore,
uptake
tumors
exceeded
that
healthy
ovaries,
most
significant
tumor-to-healthy-ovary
ratio
observed
6
These
findings
demonstrate
POLEPI,
novel
polyaldehydedextran
nanoparticle
formulation,
exhibits
enhanced
accumulation
retention
tumor
preferential
orthotopic
tumor-bearing
ovary
tissue.
provided
rapid
cost-effective
means
estimating
biodistribution,
limitations
this
method—particularly,
inability
differentiate
parent
drug
its
metabolites—were
acknowledged.
Frontiers in Cell and Developmental Biology,
Год журнала:
2025,
Номер
13
Опубликована: Апрель 7, 2025
MicroRNAs
(miRNAs)
are
small,
non-coding
RNA
molecules
that
play
a
pivotal
role
in
the
post-transcriptional
regulation
of
gene
expression.
Over
past
decade,
they
have
emerged
as
key
regulators
cancer
progression,
influencing
different
cellular
processes
such
proliferation,
apoptosis,
metastasis,
and
immune
evasion.
Their
unique
ability
to
target
multiple
genes
simultaneously
makes
miRNAs
highly
attractive
potential
therapeutic
agents
oncology.
However,
several
challenges
hindered
their
direct
clinical
application,
most
notably
inherent
instability
biological
fluids,
rapid
degradation
by
nucleases,
inefficient
delivery
specific
tumor
sites.
Additionally,
off-target
effects
for
toxicity
further
complicate
use
miRNAs.
Nanomedicine
offers
promising
solution
these
enabling
development
advanced
platforms
stable,
safe,
targeted
Nanoparticle-based
systems,
liposomes,
polymeric
nanoparticles,
inorganic
nanocarriers,
can
protect
from
degradation,
improve
bioavailability,
allow
precise
targeting
through
passive
or
active
mechanisms.
These
nanocarriers
also
be
engineered
release
response
stimuli
within
microenvironment,
enhancing
efficacy
while
minimizing
side
effects.
This
review
will
explore
integration
with
nanotechnology,
focusing
on
various
nanoparticle
formulations
roles
miRNA
stability,
specificity,
function
treatment.
In
addition,
we
discuss
current
advances
preclinical
applications,
highlight
tumor-targeting
strategies,
address
remaining
toxicity,
immunogenicity,
scalability.
Future
research
should
focus
overcoming
barriers,
ultimately
paving
way
widespread
adoption
personalized
miRNA-based
nanomedicine
therapy.
